Takeda Pharmaceutical Company Limited, commonly known as Takeda, is a leading global biopharmaceutical firm headquartered in Japan. Founded in 1781, Takeda has evolved into a prominent player in the pharmaceutical industry, with a strong presence in regions such as North America, Europe, and Asia. The company focuses on key therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases, offering innovative treatments that address unmet medical needs. Takeda is renowned for its commitment to research and development, with a robust pipeline of biologics and small molecules. Notable achievements include its strategic acquisitions and partnerships that have bolstered its market position, making it one of the largest pharmaceutical companies in the world. With a dedication to patient-centric solutions, Takeda continues to lead in delivering unique therapies that improve health outcomes globally.
How does Takeda's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Takeda's score of 65 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Takeda Pharmaceutical Company reported total greenhouse gas emissions of approximately 4,265,000,000 kg CO2e. This figure includes 279,000,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 33,000,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. The majority of their emissions, about 3,953,000,000 kg CO2e, fall under Scope 3, which includes emissions from the entire value chain, such as purchased goods and services. Takeda has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2040. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 65% by FY2030 from a FY2016 baseline, and to cut Scope 3 emissions by 25% by FY2030 from a FY2022 baseline. Long-term goals include a 90% reduction in Scope 1 and 2 emissions by FY2035 and a 90% reduction in Scope 3 emissions by FY2040. These commitments reflect Takeda's dedication to sustainability and align with industry standards for climate action, demonstrating a proactive approach to mitigating climate change impacts.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 700,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 372,244,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
Scope 3 | 3,700,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Takeda is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.